专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004108078A3 RATIONALLY DESIGNED ANTIBODIES 审中-公开
标题翻译：方案设计抗体
公开(公告)号：WO2004108078A3
公开(公告)日：2006-04-06
申请号：PCT/US2004016574
申请日：2004-05-26
申请人： ALEXION PHARMA INC , BOWDISH KATHERINE S , FREDERICKSON SHANA , RENSHAW MARK , ORENCIA CECILIA
发明人： BOWDISH KATHERINE S , FREDERICKSON SHANA , RENSHAW MARK , ORENCIA CECILIA
IPC分类号： C07K16/12 , C12N1/21 , C12N15/13 , C07K16/00 , C07H21/04
CPC分类号： C07K16/1282 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2318/10
摘要： Antibodies or fragments thereof having at least two CDR regions replaced or fused with biologically active peptides are described. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.
摘要翻译：描述了具有替换或与生物活性肽融合的至少两个CDR区的抗体或其片段。含有此类抗体或其片段的组合物可用于治疗和诊断方式。

2. 发明申请

WO2005060642A3 RATIONALLY DESIGNED ANTIBODIES 审中-公开
标题翻译：原理设计的抗体
公开(公告)号：WO2005060642A3
公开(公告)日：2005-10-27
申请号：PCT/US2004041946
申请日：2004-12-15
申请人： ALEXION PHARMA INC , BOWDISH KATHERINE S , FREDERICKSON SHANA , RENSHAW MARK , ORENCIA CECILIA
发明人： BOWDISH KATHERINE S , FREDERICKSON SHANA , RENSHAW MARK , ORENCIA CECILIA
IPC分类号： A61K39/395 , C07H21/04 , C07K14/505 , C07K14/52 , C07K16/00 , C07K16/12 , C07K16/18 , C07K16/46
CPC分类号： C07K16/00 , A61K2039/505 , C07K14/505 , C07K14/524 , C07K16/005 , C07K16/12 , C07K16/1282 , C07K16/18 , C07K16/46 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/74 , C07K2318/10 , C07K2319/00 , C07K2319/30
摘要： Antibodies or fragments thereof having CDR regions replaced or fused with biologically active peptides are described. Flanking sequences may optionally be attached at one or both the carboxy-terminal and amino-terminal ends of the peptide in covalent association with adjacent framework regions. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.
摘要翻译：描述了具有用生物活性肽替换或融合CDR区的抗体或其片段。侧翼序列可以任选地与肽的羧基末端和氨基末端中的一个或两个连接，与相邻的框架区共价结合。含有此类抗体或其片段的组合物可用于治疗和诊断方式。

3. 发明申请

WO2005082004A3 RATIONALLY DESIGNED ANTIBODIES HAVING A DOMAIN-EXCHANGED SCAFFOLD 审中-公开
标题翻译：具有域交换SCAFFOLD的方案设计抗体
公开(公告)号：WO2005082004A3
公开(公告)日：2008-10-09
申请号：PCT/US2005005879
申请日：2005-02-22
申请人： ALEXION PHARMA INC , BOWDISH KATHERINE S , FREDERICKSON SHANA , RENSHAW MARK , MARUYAMA TOSHIAKI , ORENCIA CECILIA
发明人： BOWDISH KATHERINE S , FREDERICKSON SHANA , RENSHAW MARK , MARUYAMA TOSHIAKI , ORENCIA CECILIA
IPC分类号： C07K16/00
摘要： Domain-exchanged antibodies having CDR regions replaced or fused with biologically active peptides are described. Flanking sequences may optionally be attached at one or both the carboxy-terminal and amino-terminal ends of the peptide in covalent association with adjacent framework regions. Compositions containing such modified domain-exchanged antibodies are useful in therapeutic and diagnostic modalities.
摘要翻译：描述了具有被替换或与生物活性肽融合的CDR区的域交换的抗体。侧翼序列可以任选地在肽的羧基末端和氨基末端的一个或两个连接，与相邻构架区共价结合。含有这种修饰的结构域交换抗体的组合物可用于治疗和诊断方式。

4. 发明申请

WO03025202A2 ENGINEERED TEMPLATES AND THEIR USE IN SINGLE PRIMER AMPLIFICATION 审中-公开
标题翻译：工程模板及其在单一放大器中的使用
公开(公告)号：WO03025202A2
公开(公告)日：2003-03-27
申请号：PCT/US0229889
申请日：2002-09-19
申请人： ALEXION PHARMA INC , BOWDISH KATHERINE S , FREDERICKSON SHANA , MARUYAMA TOSHIAKI , LIN YING-CHI , RENSHAW MARK
发明人： BOWDISH KATHERINE S , FREDERICKSON SHANA , MARUYAMA TOSHIAKI , LIN YING-CHI , RENSHAW MARK
IPC分类号： C12N15/09 , C12N15/10 , C12Q1/68 , C12Q
CPC分类号： C12N15/1093 , C12Q1/6844 , C12Q1/6853 , C12Q1/6855 , C12Q2537/157 , C12Q2533/101 , C12Q2525/301 , C12Q2525/186 , C12Q2525/161 , C12Q2525/155 , C12Q2525/131
摘要： Methods of amplifying nucleic acid have now been discovered which include the steps of: a) annealing a primer to a template nucleic acid sequence, the primer having a first portion which anneals to the template and a second portion of predetermined sequence; b) synthesizing a polynucleotide that anneals to and is complementary to the portion of the template between the location at which the first portion of the primer anneals to the template and the end of the template, the polynucleotide having a first end and a second end, wherein the first end incorporates the primer; c) separating the polynucleotide synthesized in step (b ) from the template; d) annealing a nested oligonucleotide to the second end of the polynucleotide synthesized in step (b), the nested oligonucleotide having a first portion that anneals to the second end of the polynucleotide and a second portion having the same predetermined sequence as the second portion of the primer; e) extending the polynucleotide synthesized in step (b) to provide a terminal portion thereof that is complementary to the predetermined sequence; and f) amplifying the extended polynucleotide using a single primer having the predetermined sequence.
摘要翻译：现已发现扩增核酸的方法，其包括以下步骤：a）将引物退火至模板核酸序列，所述引物具有与模板退火的第一部分和预定序列的第二部分; b）合成在所述模板的第一部分与所述模板退火的位置与所述模板的末端之间退火并与所述模板部分互补的多核苷酸，所述多核苷酸具有第一末端和第二末端，其中所述第一端包含所述底漆; c）将步骤（b）中合成的多核苷酸与模板分离; d）将嵌套的寡核苷酸退火到步骤（b）中合成的多核苷酸的第二末端，所述嵌套的寡核苷酸具有与所述多核苷酸的第二末端退火的第一部分和具有与所述多核苷酸的第二部分相同的预定序列的第二部分底漆; e）延伸在步骤（b）中合成的多核苷酸以提供与预定序列互补的其末端部分; 和f）使用具有预定序列的单一引物扩增延伸的多核苷酸。

5. 发明申请

WO2005060641A3 ENGINEERED TEMPLATES AND THEIR USE IN SINGLE PRIMER AMPLIFICATION 审中-公开
标题翻译：工程模板及其在单一放大器中的使用
公开(公告)号：WO2005060641A3
公开(公告)日：2008-02-21
申请号：PCT/US2004041945
申请日：2004-12-15
申请人： ALEXION PHARMA INC , MARUYAMA TOSHIAKI , FREDERICKSON SHANA , BOWDISH KATHERINE S , RENSHAW MARK , LIN YING-CHI
发明人： MARUYAMA TOSHIAKI , FREDERICKSON SHANA , BOWDISH KATHERINE S , RENSHAW MARK , LIN YING-CHI
IPC分类号： C12Q1/68 , C07K16/00 , C07K16/08 , C07K16/42 , C12N15/10 , C12N15/11 , C12P19/34
CPC分类号： C07K16/4291 , C07K16/005 , C07K16/082 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C12N15/1093 , C12Q1/6844 , C12Q1/6853 , C12Q1/6855 , C12Q1/686 , Y10S530/861 , C12Q2525/161 , C12Q2525/155 , C12Q2537/157 , C12Q2533/101 , C12Q2525/301 , C12Q2525/131 , C12Q2525/186
摘要： Methods of amplifying nucleic acid have now been discovered which include the steps of: a) annealing a primer to a template nucleic acid sequence, the primer having a first portion which anneals to the template and a second portion of predetermined sequence; b) synthesizing a polynucleotide that anneals to and is complementary to the portion of the template between the location at which the first portion of the primer anneals to the template and the end of the template, the polynucleotide having a first end and a second end, wherein the first end incorporates the primer; c) separating the polynucleotide synthesized in step (b) from the template; d) annealing a nested oligonucleotide to the second end of the polynucleotide synthesized in step (b), the nested oligonucleotide having a first portion that anneals to the second end of the polynucleotide and a second portion having the same predetermined sequence as the second portion of the primer; e) extending the polynucleotide synthesized in step (b) to provide a terminal portion thereof that is complementary to the predetermined sequence; and f) amplifying the extended polynucleotide using a single primer having the predetermined sequence. In particularly useful embodiments, the methods are used to amplify a repertoire of IgA antibodies.
摘要翻译：现已发现扩增核酸的方法，其包括以下步骤：a）将引物退火至模板核酸序列，所述引物具有与模板退火的第一部分和预定序列的第二部分; b）合成在所述模板的第一部分与所述模板退火的位置与所述模板的末端之间退火并与所述模板部分互补的多核苷酸，所述多核苷酸具有第一末端和第二末端，其中所述第一端包含所述底漆; c）将步骤（b）中合成的多核苷酸与模板分离; d）将嵌套的寡核苷酸退火到步骤（b）中合成的多核苷酸的第二末端，所述嵌套的寡核苷酸具有与所述多核苷酸的第二末端退火的第一部分和具有与所述多核苷酸的第二部分相同的预定序列的第二部分底漆; e）延伸在步骤（b）中合成的多核苷酸以提供与预定序列互补的其末端部分; 和f）使用具有预定序列的单一引物扩增延伸的多核苷酸。在特别有用的实施方案中，所述方法用于扩增IgA抗体的所有组成成分。

6. 发明申请

WO03025019A8 ANTI-PDGF ANTIBODIES AND METHODS FOR PRODUCING ENGINEERED ANTIBODIES 审中-公开
标题翻译：抗PDGF抗体和生产工程抗体的方法
公开(公告)号：WO03025019A8
公开(公告)日：2004-04-01
申请号：PCT/US0230086
申请日：2002-09-20
申请人： ALEXION PHARMA INC , BOWDISH KATHERINE S , FREDERICKSON SHANA , KRETZ-ROMMEL ANKE
发明人： BOWDISH KATHERINE S , FREDERICKSON SHANA , KRETZ-ROMMEL ANKE
IPC分类号： C12N15/09 , A61K39/395 , A61K45/00 , A61P35/00 , A61P43/00 , C07K16/22 , C07K16/26 , C07K16/46 , C07K16/00 , C07K16/28 , C12N15/00
CPC分类号： C07K16/464 , A61K2039/505 , C07K16/22 , C07K2317/73
摘要： Methods of making and selecting engineered antibodies and/or antibody fragments provide maximized binding affinity for a predetermined target and minimized immunogenicity when such antibodies are administered to a target species. Libraries containing variants of the engineered antibodies are also provided. In particularly useful embodiments, anti-PGDF antibodies and compositions are produced which are useful in the treatment of various cancers.
摘要翻译：制造和选择工程化抗体和/或抗体片段的方法为预定靶标提供最大化的结合亲和力，并且当将这样的抗体施用于靶物种时使免疫原性最小化。还提供了含有工程化抗体变体的文库。在特别有用的实施方案中，产生可用于治疗各种癌症的抗PGDF抗体和组合物。

7. 发明申请

WO2004078937A3 VECTORS USED TO CREATE HYBRID CONSTANT REGIONS 审中-公开
标题翻译：用于创建混合型恒定区域的矢量图
公开(公告)号：WO2004078937A3
公开(公告)日：2005-12-22
申请号：PCT/US2004006571
申请日：2004-03-04
申请人： ALEXION PHARMA INC , BOWDISH KATHERINE S , FREDERICKSON SHANA , MARUYAMA TOSHIAKI
发明人： BOWDISH KATHERINE S , FREDERICKSON SHANA , MARUYAMA TOSHIAKI
IPC分类号： C07K16/00 , C07K16/22 , C12N15/63 , C12N15/00 , G01N33/53
CPC分类号： C07K16/22 , C07K16/005 , C07K2317/24 , C07K2317/55
摘要： Expression vectors used for expression of mouse Fab libraries and expression of individual clones have portions of mouse constant regions replaced with human constant regions while maintaining desired cloning sites.
摘要翻译：用于表达小鼠Fab文库的表达载体和单个克隆的表达在保持所需的克隆位点的同时保留了用人恒定区替换的部分小鼠恒定区。

8. 发明申请

WO2004110362A3 IMMUNOTHERAPEUTICS FOR BIODEFENSE 审中-公开
标题翻译：生物识别免疫学
公开(公告)号：WO2004110362A3
公开(公告)日：2005-07-28
申请号：PCT/US2004016557
申请日：2004-05-26
申请人： ALEXION PHARMA INC , BOWDISH KATHERINE S , FREDERICKSON SHANA , WILD MARTHA A , MARUYAMA TOSHIAKI , NOLAN MARY JEAN
发明人： BOWDISH KATHERINE S , FREDERICKSON SHANA , WILD MARTHA A , MARUYAMA TOSHIAKI , NOLAN MARY JEAN
IPC分类号： A61K20060101 , A61K38/00 , C07K16/08 , C07K16/10 , C07K16/12 , C12N15/10
CPC分类号： C07K16/08 , A61K2039/505 , C07K16/1081 , C07K16/1278 , C07K2317/21 , C07K2317/55 , C12N15/1034
摘要： Human neutralizing antibodies (full-length or functional fragments) are useful as anti-toxins or anti-infectives with respect to infective agents such as, for example, anthrax, botulinum, smallpox, Venezuelan equine encephalomyelitis virus (VEEV), West Nile virus (WNV) and the like.
摘要翻译：人中和抗体（全长或功能片段）可用作抗感染剂或抗感染药物，例如炭疽，肉毒杆菌，天花，委内瑞兰马脑脊髓炎病毒（VEEV），西尼罗病毒 WNV）等。

9. 发明申请

WO03025019A9 ANTI-PDGF ANTIBODIES AND METHODS FOR PRODUCING ENGINEERED ANTIBODIES 审中-公开
标题翻译：抗PDGF抗体和生产工程抗体的方法
公开(公告)号：WO03025019A9
公开(公告)日：2004-05-06
申请号：PCT/US0230086
申请日：2002-09-20
申请人： ALEXION PHARMA INC , BOWDISH KATHERINE S , FREDERICKSON SHANA , KRETZ-ROMMEL ANKE
发明人： BOWDISH KATHERINE S , FREDERICKSON SHANA , KRETZ-ROMMEL ANKE
IPC分类号： C12N15/09 , A61K39/395 , A61K45/00 , A61P35/00 , A61P43/00 , C07K16/22 , C07K16/26 , C07K16/46 , C07K16/00 , C07K16/28 , C12N15/00
CPC分类号： C07K16/464 , A61K2039/505 , C07K16/22 , C07K2317/73
摘要： Methods of making and selecting engineered antibodies and/or antibody fragments provide maximized binding affinity for a predetermined target and minimized immunogenicity when such antibodies are administered to a target species. Libraries containing variants of the engineered antibodies are also provided. In particularly useful embodiments, anti-PGDF antibodies and compositions are produced which are useful in the treatment of various cancers.
摘要翻译：制备和选择工程化抗体和/或抗体片段的方法为预定靶标提供最大化的结合亲和力，并且当将这种抗体施用于靶物种时，其最小化免疫原性。还提供了含有工程化抗体变体的文库。在特别有用的实施方案中，制备可用于治疗各种癌症的抗PGDF抗体和组合物。

10. 发明申请

WO2004039234A2 HUMANIZED ANTIBODIES AGAINST THE VENEZUELAN EQUINE ENCEPHALITIS VIRUS 审中-公开
标题翻译：人体抗原对维生素EQUINE ENCEPHALITIS病毒的抗体
公开(公告)号：WO2004039234A2
公开(公告)日：2004-05-13
申请号：PCT/US0315083
申请日：2003-05-13
申请人： ALEXION PHARMA INC , FREDERICKSON SHANA , HINKEL CHRIS
发明人： FREDERICKSON SHANA , HINKEL CHRIS
IPC分类号： C12N15/09 , A61K39/395 , A61P31/12 , C07K16/10 , C07K16/18 , C07K16/22 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/02 , C12N15/13 , C12P21/08 , A61B
CPC分类号： C07K16/22 , A61K2039/505 , C07K16/464 , C07K2317/24 , C07K2317/55
摘要： Humanized anti-VEEV antibodies can be used to prevent and/or neutralize viral infection.
摘要翻译：人源化抗VEEV抗体可用于预防和/或中和病毒感染。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式